Hasegawa Eiichi, Takeda Atsunobu, Yawata Nobuyo, Sonoda Koh-Hei
Department of Ophthalmology, Kyushu University Graduate School of Medicine , Fukuoka , Japan.
National Hospital Organization Kyushu Medical Center , Fukuoka , Japan.
Immunol Med. 2019 Jun;42(2):79-83. doi: 10.1080/25785826.2019.1642080. Epub 2019 Jul 17.
Uveitis, which is a major cause of blindness worldwide, is defined as intraocular inflammation that affects the iris, ciliary body, vitreous, retina and choroid. Tumor necrosis factor-alpha (TNF-α) is a key cytokine involved in the pathogenesis of many inflammatory diseases including uveitis. Corticosteroids and immunosuppressive agents are the conventional therapy to treat non-infectious uveitis. In cases that are resistant to these therapies, anti-TNF agents are added. An anti-TNF-α agent, adalimumab, was recently approved for the treatment of refractory non-infectious uveitis. In this review, we provide an introduction to uveitis and summarize the effectiveness and safety of adalimumab in the treatment of non-infectious uveitis.
葡萄膜炎是全球失明的主要原因之一，被定义为影响虹膜、睫状体、玻璃体、视网膜和脉络膜的眼内炎症。肿瘤坏死因子-α（TNF-α）是许多炎症性疾病（包括葡萄膜炎）发病机制中的关键细胞因子。皮质类固醇和免疫抑制剂是治疗非感染性葡萄膜炎的传统疗法。对于对这些疗法耐药的病例，则加用抗TNF药物。一种抗TNF-α药物阿达木单抗最近被批准用于治疗难治性非感染性葡萄膜炎。在本综述中，我们介绍了葡萄膜炎，并总结了阿达木单抗治疗非感染性葡萄膜炎的有效性和安全性。
